EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study

Hildur Helgadottir, Lars Ny, Gustav J Ullenhag, Rasmus Mikiver, Karolin Isaksson, Roger Olofsson Bagge

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2025.116201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Hildur Helgadottir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Pathology, Karolinska Institutet, Stockholm 171 77, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm 171 76…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Region Stockholm, Cancerfonden, Cancer Research Foundations of Radiumhemmet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsImmune Checkpoint InhibitorsHumansFemaleRegistriesMaleChemotherapy, AdjuvantAgedSwedenMiddle AgedNeoplasm StagingAdultSurvival RateSentinel Lymph Node Biopsy

Stichwörter der Autor:innen

Adjuvant treatmentBRAF and MEK inhibitorsImmune checkpoint inhibitorsMelanomaOverall survivalPD-1 inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology and Pathology, Karolinska Institutet, Stockholm 171 77, Sweden; Theme Cancer, Karolinska University Hospital, Stockholm 171 76, Sweden. Electronic address: hildur.helgadottir@sll.se.
  • Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg 418 77, Sweden; Department of Oncology, Sahlgrenska University Hospita…
  • Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala 751 85, Sweden; Department of Oncology, Uppsala University Hospital, Entrance 101, First Level, Uppsala 751 85, Sweden. E…
  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping 581 83, Sweden; Regional Cancer Center South East Sweden, Regional Cancer Center Southeast Sweden and Department of Clinical and Experiment…
  • Department of Clinical Sciences, Surgery, Lund University, Lund 22100, Sweden; Department of Surgery, Skåne University Hospital, Kristianstad 29133, Sweden. Electronic address: karolin.isaksson@med.lu.se.
  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden; Department of Surgery, Sahlgrenska University Hospital, Västra Götalandsregionen, Gothenbur…

Förderung

  • Region Stockholm
  • Cancerfonden
  • Cancer Research Foundations of Radiumhemmet

Zitieren

APA

Helgadottir, H., Ny, L., Ullenhag, G. J., Mikiver, R., Isaksson, K., & Olofsson Bagge, R. (2026). Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116201

Vancouver

Helgadottir H, Ny L, Ullenhag GJ, Mikiver R, Isaksson K, Olofsson Bagge R. Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116201

BibTeX
@article{Helgadottir2026,
  author = {Helgadottir, Hildur and Ny, Lars and Ullenhag, Gustav J and Mikiver, Rasmus and Isaksson, Karolin and Olofsson Bagge, Roger},
  title = {Five-year survival after introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2025.116201}
}
Kostenlos starten →